Health groups urges govt to rescind Gilead's patents for COVID-19 drug remdesivir; say move to ensure fair distribution

The aid group Doctors Without Borders has also opposed Gilead’s patents on remdesivir, saying such licensing pacts are “not acceptable” amid a global health emergency.

Reuters May 14, 2020 18:37:00 IST
Health groups urges govt to rescind Gilead's patents for COVID-19 drug remdesivir; say move to ensure fair distribution

New Delhi: Two health advocacy groups have written to the Indian government asking it to rescind patents given to Gilead Sciences for the drug remdesivir so it can be distributed more fairly to coronavirus patients around the world, particularly in poorer nations.

Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical drugs to them. Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola.

Remdesivir is the only drug approved to treat COVID-19 patients after promising early trial results prompted U.S. regulators to grant emergency use authorisation on 2 May.

Health groups urges govt to rescind Gileads patents for COVID19 drug remdesivir say move to ensure fair distribution

Representational image. PTI

To expand its access, Gilead said this week it had signed non-exclusive licensing pacts here with five generic drugmakers based in India and Pakistan, allowing them to make and sell remdesivir for 127 countries.

But health access groups say the pacts mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers.

Click here to follow LIVE updates on coronavirus outbreak

“The licenses divide the global market into two and profitable markets are retained with Gilead and less profitable markets are given to the five generic companies,” said K Gopakumar, senior legal researcher at Third World Network, which sent a letter to the Indian government on Wednesday.

The letter by Third World Network, a Malaysia-based non-profit group, followed a similar appeal by India’s Cancer Patients Aid Association last week.

The aid group Doctors Without Borders has also opposed Gilead’s patents on remdesivir, saying such licensing pacts are “not acceptable” amid a global health emergency.

Gilead’s patents on remdesivir in India allow it to exclusively make and sell the drug in the country until 2035 unless it licenses those rights out.

A Gilead spokeswoman told Reuters in an email that the company is “actively considering every potential pathway” to make the drug available to those who need it as fast as possible.

She said the company was in talks with the UN-backed Medicines Patent Pool and the United Nations Children’s Fund to expand access to it.

“Compulsory licensing will not solve the challenge of limited supply,” the spokeswoman said, referring to a provision under which countries can allow manufacturers to make certain drugs without the patent owner’s consent.

India’s commerce and health ministries did not immediately respond to emails seeking comment.

India’s Cancer Patients Aid Association said it might pursue legal action, noting that cancer patients have compromised immunity and are highly susceptible to the virus.

“It is imperative at a time like this that no monopoly rights be granted, so that more manufacturers can produce the drug to be made available to all the people who need it, at affordable costs,” it said.

Except for remdesivir, there are currently no other drugs or vaccines approved to fight coronavirus, which has killed more than 200,000 people globally.

Updated Date:

also read

Mumbai records 2,479 COVID cases in 24 hours, tally 50% higher than Wednesday
Health

Mumbai records 2,479 COVID cases in 24 hours, tally 50% higher than Wednesday

Meanwhile, Maharashtra reported 5,218 new COVID-19 cases on Thursday. It is among ten other states which have been recording over 1,000 active cases

Wimbledon 2022: Positive COVID-19 cases create chaos at the All England Club
Tennis

Wimbledon 2022: Positive COVID-19 cases create chaos at the All England Club

At Wimbledon, All England Club is following British government guidance that requires neither shots nor testing, three of the top-20 seeded men have withdrawn.

India logs 17,336 new COVID-19 cases in last 24 hours, up 30% from yesterday; positivity rate jumps to 4.32%
India

India logs 17,336 new COVID-19 cases in last 24 hours, up 30% from yesterday; positivity rate jumps to 4.32%

Delhi and Maharashtra reported the maximum number of COVID-19 cases in the last 24 hours. As many as 13 people died of COVID-19, increasing the cumulative casualty due to the virus in the country to 5,24,954